• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用一种计算方法鉴定出的与高危乳腺癌患者相关的生物学关联。

Biological correlates associated with high-risk breast cancer patients identified using a computational method.

作者信息

Oh Jung Hun, Pareja Fresia, Elkin Rena, Xu Kaiming, Norton Larry, Deasy Joseph O

机构信息

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

NPJ Breast Cancer. 2025 Jan 29;11(1):8. doi: 10.1038/s41523-025-00725-y.

DOI:10.1038/s41523-025-00725-y
PMID:39875417
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11775240/
Abstract

Using a novel unsupervised method to integrate multi-omic data, we previously identified a breast cancer group with a poor prognosis. In the current study, we characterize the biological features of this subgroup, defined as the high-risk group, using various data sources. Assessment of three published hypoxia signatures showed that the high-risk group exhibited higher hypoxia scores (p < 0.0001 in all three signatures), compared to the low-risk group. Our analysis of the immune cell composition using CIBERSORT and leukocyte fraction showed significant differences between the high and low-risk groups across the entire cohort, as well as within PAM50 subtypes. Within the basal subtype, the low-risk group had a statistically significantly higher spatial fraction of tumor-infiltrating lymphocytes (TILs) compared to the high-risk group (p = 0.0362). Our findings indicate that this subgroup with poor prognosis is driven by a distinct biological signature with high activation of hypoxia-related genes as well as a low number of TILs.

摘要

我们先前使用一种新型无监督方法整合多组学数据,鉴定出了一个预后不良的乳腺癌组。在当前研究中,我们使用各种数据源来描述这个被定义为高风险组的亚组的生物学特征。对三个已发表的缺氧特征的评估表明,与低风险组相比,高风险组表现出更高的缺氧评分(在所有三个特征中p < 0.0001)。我们使用CIBERSORT和白细胞分数对免疫细胞组成进行的分析表明,在整个队列以及PAM50亚型中,高风险组和低风险组之间存在显著差异。在基底亚型中,与高风险组相比,低风险组的肿瘤浸润淋巴细胞(TILs)空间分数在统计学上显著更高(p = 0.0362)。我们的研究结果表明,这个预后不良的亚组是由一种独特的生物学特征驱动的,该特征具有缺氧相关基因的高激活以及低数量的TILs。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/152029bba50b/41523_2025_725_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/04461bac8408/41523_2025_725_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/470efa3469a3/41523_2025_725_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/a00e6605d639/41523_2025_725_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/d15c9fc81a66/41523_2025_725_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/8e4fd5a0b004/41523_2025_725_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/68580601da56/41523_2025_725_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/152029bba50b/41523_2025_725_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/04461bac8408/41523_2025_725_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/470efa3469a3/41523_2025_725_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/a00e6605d639/41523_2025_725_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/d15c9fc81a66/41523_2025_725_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/8e4fd5a0b004/41523_2025_725_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/68580601da56/41523_2025_725_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d9b/11775240/152029bba50b/41523_2025_725_Fig7_HTML.jpg

相似文献

1
Biological correlates associated with high-risk breast cancer patients identified using a computational method.使用一种计算方法鉴定出的与高危乳腺癌患者相关的生物学关联。
NPJ Breast Cancer. 2025 Jan 29;11(1):8. doi: 10.1038/s41523-025-00725-y.
2
Genomic Characteristics Related to Histology-Based Immune Features in Breast Cancer.与乳腺癌基于组织学的免疫特征相关的基因组特征
Mod Pathol. 2025 May;38(5):100736. doi: 10.1016/j.modpat.2025.100736. Epub 2025 Feb 15.
3
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.切洛布试验中化疗和曲妥珠单抗治疗的 HER2 阳性乳腺癌患者的 PAM50 亚型综合评估和免疫调节。
Ann Oncol. 2016 Oct;27(10):1867-73. doi: 10.1093/annonc/mdw262. Epub 2016 Aug 2.
4
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.早期 ERBB2/HER2 阳性乳腺癌中免疫相关基因表达特征与肿瘤浸润淋巴细胞的预后和预测价值:CALGB 40601 和 PAMELA 试验的相关性分析。
JAMA Oncol. 2023 Apr 1;9(4):490-499. doi: 10.1001/jamaoncol.2022.6288.
5
Multi-Omic Regulation of the PAM50 Gene Signature in Breast Cancer Molecular Subtypes.乳腺癌分子亚型中PAM50基因特征的多组学调控
Front Oncol. 2020 May 22;10:845. doi: 10.3389/fonc.2020.00845. eCollection 2020.
6
Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.结肠癌中缺氧相关亚型的鉴定、预后模型的建立及肿瘤微环境浸润特征
Front Genet. 2022 Jun 17;13:919389. doi: 10.3389/fgene.2022.919389. eCollection 2022.
7
Research-based PAM50 signature and long-term breast cancer survival.基于研究的 PAM50 标志物与长期乳腺癌生存
Breast Cancer Res Treat. 2020 Jan;179(1):197-206. doi: 10.1007/s10549-019-05446-y. Epub 2019 Sep 21.
8
Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer.磁共振成像与乳腺癌肿瘤浸润淋巴细胞相关的分子特征。
Breast Cancer Res. 2018 Sep 3;20(1):101. doi: 10.1186/s13058-018-1039-2.
9
Benefits of Targeted Molecular Therapy to Immune Infiltration and Immune-Related Genes Predicting Signature in Breast Cancer.靶向分子疗法对乳腺癌免疫浸润及预测特征的免疫相关基因的益处。
Front Oncol. 2022 Mar 4;12:824166. doi: 10.3389/fonc.2022.824166. eCollection 2022.
10
Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya.在肯尼亚西部侵袭性乳腺癌中,肿瘤浸润白细胞密度与肿瘤分级和分子亚型无关。
Trop Med Health. 2017 Aug 4;45:19. doi: 10.1186/s41182-017-0059-4. eCollection 2017.

引用本文的文献

1
Unveiling GBE1 as a hypoxia-related prognostic gene with significant impact on immune cell infiltration in HER2-enriched breast cancer.揭示GBE1作为一种与缺氧相关的预后基因,对HER2富集型乳腺癌中的免疫细胞浸润有显著影响。
Discov Oncol. 2025 Jun 1;16(1):975. doi: 10.1007/s12672-025-02826-3.

本文引用的文献

1
PIK3CA mutations in endocrine-resistant breast cancer.内分泌耐药性乳腺癌中的 PIK3CA 突变。
Sci Rep. 2024 May 31;14(1):12542. doi: 10.1038/s41598-024-62664-1.
2
The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer.VEGF-缺氧特征在非洲裔女性的基底样乳腺癌中上调,并与乳腺癌不良预后相关。
Clin Cancer Res. 2024 Jun 3;30(11):2609-2618. doi: 10.1158/1078-0432.CCR-23-1526.
3
Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes.
乳腺癌亚型中对新辅助化疗反应的预后意义
J Chemother. 2025 Feb;37(1):60-68. doi: 10.1080/1120009X.2024.2314830. Epub 2024 Feb 13.
4
TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects.亚洲乳腺癌中的 TP53 体细胞突变与亚型特异性效应相关。
Breast Cancer Res. 2023 Apr 26;25(1):48. doi: 10.1186/s13058-023-01635-2.
5
Role of p53 in breast cancer progression: An insight into p53 targeted therapy.p53 在乳腺癌进展中的作用:对 p53 靶向治疗的深入了解。
Theranostics. 2023 Feb 27;13(4):1421-1442. doi: 10.7150/thno.81847. eCollection 2023.
6
PIK3CA-mutations in breast cancer.乳腺癌中的 PIK3CA 突变。
Breast Cancer Res Treat. 2022 Dec;196(3):483-493. doi: 10.1007/s10549-022-06637-w. Epub 2022 Oct 24.
7
Molecular analysis of TCGA breast cancer histologic types.癌症基因组图谱(TCGA)乳腺癌组织学类型的分子分析。
Cell Genom. 2021 Dec 8;1(3). doi: 10.1016/j.xgen.2021.100067.
8
vWCluster: Vector-valued optimal transport for network based clustering using multi-omics data in breast cancer.vWCluster:基于网络的乳腺癌多组学数据聚类的向量值最优传输。
PLoS One. 2022 Mar 14;17(3):e0265150. doi: 10.1371/journal.pone.0265150. eCollection 2022.
9
Breast Cancer Heterogeneity.乳腺癌异质性
Diagnostics (Basel). 2021 Aug 27;11(9):1555. doi: 10.3390/diagnostics11091555.
10
Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression.以乳腺癌为例,探讨肿瘤异质性和肿瘤细胞可塑性在恶性进展过程中的作用。
Br J Cancer. 2021 Jul;125(2):164-175. doi: 10.1038/s41416-021-01328-7. Epub 2021 Apr 6.